Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
During 1985–1990 the U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug screening program and developed as the replacement a new in vitro primary screen based upon a diverse panel of human tumor cell lines. For each substance tested, the screen generates a remarkably reproducible and characteristic profile of differential in vitro cellular sensitivity, or lack thereof, across the 60 different cell lines comprising the panel. Several investigational approaches to display, analysis, and interpretation of such profiles and databases, derived from the testing of tens of thousands of substances during the past 4–5 years since the NCI screen became fully operational, have been explored. A variety of useful, practical applications of the in vitro screen have become apparent. As these applications continue to evolve, they are proving to be complementary to diverse other anticancer screening and drug discovery strategies being developed or pursued elsewhere. Reviewed herein are some practical considerations and selected specific examples, particularly illustrating research applications of the NCI screen that may be more broadly applicable to the search for new anticancer drug development leads with novel profiles of antitumor activity and/or mechanisms of action. © 1995 Wiley‐Liss, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, in December 1992, MDA‐MB‐435 was added to the NCI‐60 cell line panel for use in anticancer drug screening, where it was initially described as a “breast” cancer cell line.17”
From Authentication of M14 melanoma cell line proves misidentification of MDA‐MB‐435 breast cancer cell line (2018) · cites this paper as [17]
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Self-citationMonks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Self-citationA Human Cell Line From a Pleural Effusion Derived From a Breast Carcinoma 2
Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1409 · Cited by 2,449
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
Kaighn, M. E., Ks, N., Ohnuki, Y., Lechner, J. F., & Jones, L. W. (1979) · PubMed · Cited by 2,121
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015
Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., & Boyd, M. R. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.14.1088 · Cited by 967
Self-citationRubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1113 · Cited by 927
Self-citationIsolation of a human prostate carcinoma cell line (DU 145)
Stone, K. R., Mickey, D. D., Wunderli, H., Mickey, G. H., & Paulson, D. F. (1978) · International Journal of Cancer · doi:10.1002/ijc.2910210305 · Cited by 926
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679
Establishment and characterization of a cell line of human breast carcinoma origin
Keydar, I., Chen, L., Karby, S., Weiss, F. R., Delarea, J., Radu, M., Chaitcik, S., & Brenner, H. J. (1979) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(79)90139-7 · Cited by 650
Research works printed but not linked: 6
- Acton EM, 1992, Anticancer specificity of some ellipticinium salts against human brain tumors in vitro, Proc Am Assoc Cancer Res, 33, 488
- Boyd MR, 1986, Accomplishments in Oncology, Vol 1, Cancer Therapy: Where Do We Go From Here?, 68
- Boyd MR, 1989, Cancer: Principles and Practice of Oncology Updates, 1
- Buolamwini JK, 1994, Searching for new molecular targets for therapy of cancer and AIDS: Characterization by 2D protein gel electrophoresis, Proc Am Assoc Cancer Res, 35, 613
- Grever MR, 1994, Status of in vivo evaluations in the NCI anticancer drug discovery program, Proc Am Assoc Cancer Res, 35, 369
- Stinson SF, 1992, Morphologic and immunocytochemical characteristics of human tumor cell lines for use in an anticancer drug screen, Anticancer Res, 12, 1035
Cited by
Items 101–200 of 1,000
Al-Omary, F. A. M., Abou-zeid, L. A., Nagi, M. N., Habib, E. E., Abdel‐Aziz, A. A. ‐., El‐Azab, A. S., Abdel‐Hamide, S. G., Al-Omar, M. A., Al-Obaid, A. M., & El‐Subbagh, H. I. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.019 · Cited by 132
Stefely, J. A., Palchaudhuri, R., Miller, P. A., Peterson, R. J., Moraski, G. C., Hergenrother, P. J., & Miller, M. J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1000979 · Cited by 149
Synthesis and in vitro antitumoral activity of new hydrazinopyrimidine-5-carbonitrile derivatives
Cocco, M. T., Congiu, C., Lilliu, V., & Onnis, V. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.012 · Cited by 131
Carter, S. L., Eklund, A. C., Mecham, B. H., Kohane, I. S., & Szallasi, Z. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-107 · Cited by 131
Katariya, K., Shah, S. R., & Reddy, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103406 · Cited by 129
Luzina, E. L., & Popov, A. V. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.08.007 · Cited by 134
Ramírez–Prada, J., Robledo, S. M., Vélez, I. D., Crespo, M. D. P., Jairo Quiroga, P., Abonía, R., Montoya, A. L., Svetaz, L. A., Zacchino, S. A., & Braulio Insuasty, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.016 · Cited by 127
Marine Microorganisms and Drug Discovery: Current Status and Future Potential
Jensen, P. R., & Fenical, W. (2000) · KARGER eBooks · doi:10.1159/000062490 · Cited by 127
Design, synthesis and ADMET prediction of bis-benzimidazole as anticancer agent
Rashid, M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103576 · Cited by 126
Noolvi, M. N., Patel, H., Singh, N., Gadad, A. K., Cameotra, S. S., & Badiger, A. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.012 · Cited by 126
Diversity of DNA topoisomerases I and inhibitors
Pommier, Y. G. (1998) · Biochimie · doi:10.1016/s0300-9084(98)80008-4 · Cited by 124
Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.
Tinley, T. L., Randall‐Hlubek, D. A., Leal, R. M., Jackson, E. M., Cessac, J. W., Quada, J. C., Hemscheidt, T. K., & Mooberry, S. L. (2003) · PubMed · Cited by 137
Risinger, A. L., Jackson, E. M., Polin, L., Helms, G. L., LeBoeuf, D. A., Joe, P. A., Hopper-Borge, E. A., Ludueña, R. F., Kruh, G. D., & Mooberry, S. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2037 · Cited by 123
Dimmock, J. R., Kandepu, N., Nazarali, A. J., Kowalchuk, T. P., Motaganahalli, N. L., Quail, J. W., Mykytiuk, P. A., Audette, G. F., Prasad, L. G., Perjési, P., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9806695 · Cited by 122
El-Hawash, S. A., Habib, N. S., & Kassem, M. A. (2006) · Archiv der Pharmazie · doi:10.1002/ardp.200600061 · Cited by 122
Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells
Johansson, S., Lindholm, P., Gullbo, J., Larsson, R., Bohlin, L., & Claeson, P. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200106000-00009 · Cited by 121
Holla, B. S., Rao, B. S., Sarojini, B. K., Akberali, P. M., & Kumari, S. (2006) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2006.02.001 · Cited by 121
A new anti-tubulin agent containing the benzo[b]thiophene ring system
Pinney, K. G., Bounds, A. D., Dingeman, K. M., Mocharla, V. P., Pettit, G. R., Bai, R., & Hamel, E. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00143-2 · Cited by 120
Hydrogen Sulfide Biology and Its Role in Cancer
Khattak, S., Rauf, M. A., Khan, N. H., Zhang, Q.-Q., Chen, H., Muhammad, P., Ansari, M. A., Alomary, M. N., Jahangir, M., Zhang, C., et al. (2022) · Molecules · doi:10.3390/molecules27113389 · Cited by 119
Hranjec, M., Pavlović, G., Marjanović, M., Kralj, M., & Karminski-Zamola, G. M. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.02.022 · Cited by 119
Wosikowski, K., Schuurhuis, D., Johnson, K., Bates, S. E., Paull, K. D., Myers, T. G., & Weinstein, J. N. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.20.1505 · Cited by 119
Self-citationDemirayak, Ş., Kayağil, İ., & Yurttaş, L. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.11.007 · Cited by 119
Abo-Ashour, M. F., Eldehna, W. M., George, R. F., Abdel‐Aziz, M. M., Elaasser, M. M., Gawad, N. M. A., Gupta, A., Bhakta, S., & Abou‐Seri, S. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.008 · Cited by 116
CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
Hjarnaa, P. V., Jonsson, E. W., Latini, S., Dhar, S., Larsson, R., Bramm, E., Skov, T., & Binderup, L. (1999) · PubMed · Cited by 115
Ryan, D. P., Supko, J. G., Eder, J. P., Seiden, M. V., Demetri, G. D., Lynch, T. J., Fischman, A. J., Davis, J., Jimeno, J. A., & Clark, J. W. (2001) · PubMed · Cited by 115
Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents
El‐Nassan, H. B. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.01.031 · Cited by 120
One pot synthesis of thiazolodihydropyrimidinones and evaluation of their anticancer activity
Holla, B. S., Rao, B. S., Sarojini, B. K., & Akberali, P. M. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.06.001 · Cited by 114
Kassab, A. E., Gedawy, E. M., Hamed, M. I. A., Doghish, A. S., & Hassan, R. A. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2021.1901089 · Cited by 113
Belofsky, G. N., Jensen, P. R., Renner, M. K., & Fenical, W. (1998) · Tetrahedron · doi:10.1016/s0040-4020(97)10396-9 · Cited by 113
Takemura, H., Rao, V. A., Sordet, O., Furuta, T., Miao, Z.-H., Meng, L., Zhang, H., & Pommier, Y. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603747200 · Cited by 108
González‐Vallinas, M., Molina, S., Vicente, G., de la Cueva, A., Vargas, T., Santoyo, S., García‐Risco, M. R., Fornari, T., Reglero, G., & de Molina, A. R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.03.010 · Cited by 111
Leese, M. P., Leblond, B., Smith, A., Newman, S. P., Fiore, A. D., Simone, G. D., Supuran, C. T., Purohit, A., Reed, M. J., & Potter, B. V. L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060705x · Cited by 115
Thymidylate synthase inhibitors.
Touroutoglou, N., & Pazdur, R. (1996) · PubMed · Cited by 111
Synthesis and in vitro antitumor activity of new quinoxaline derivatives
Corona, P., Carta, A., Loriga, M., Vitale, G., & Paglietti, G. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.07.025 · Cited by 109
Wickström, M., Danielsson, K., Rickardson, L., Gullbo, J., Nygren, P., Isaksson, A., Larsson, R. L., & Lövborg, H. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.08.016 · Cited by 109
Polycyclic xanthone natural products: structure, biological activity and chemical synthesis
Winter, D. K., Sloman, D. L., & Porco, J. A. J. (2013) · Natural Product Reports · doi:10.1039/c3np20122h · Cited by 109
Synthesis and Anticancer Activity of Isatin‐Based Pyrazolines and Thiazolidines Conjugates
Havrylyuk, D., Kovach, N. A., Zimenkovsky, B. S., Vasylenko, O., & Lesyk, R. (2011) · Archiv der Pharmazie · doi:10.1002/ardp.201100055 · Cited by 108
Bashir, R., Ovais, S., Yaseen, S., Hamid, H., Alam, M. S., Samim, M., Singh, S., & Javed, K. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.05.061 · Cited by 108
Husain, A., Rashid, M., Mishra, R., Parveen, S., Shin, D., & Kumar, D. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.038 · Cited by 107
Wipf, P., Fritch, P. C., Geib, S. J., & Sefler, A. M. (1998) · Journal of the American Chemical Society · doi:10.1021/ja973580h · Cited by 107
Lüth, A., & Löwe, W. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.09.018 · Cited by 111
Lee, J. K., Bussey, K. J., Gwadry, F. G., Reinhold, W., Riddick, G., Pelletier, S. L., Nishizuka, S., Szakacs, G., Annereau, J.-P., Shankavaram, U., et al. (2003) · Genome Biology · doi:10.1186/gb-2003-4-12-r82 · Cited by 107
Inhibition of human tumor cell proliferation by novel anthraquinones from daylilies
Cichewicz, R. H., Zhang, Y., Seeram, N. P., & Nair, M. G. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.08.034 · Cited by 113
Gürsoy, A., & Karali, N. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00085-0 · Cited by 106
Shi, L. M., Fan, Y., Myers, T. G., O'Connor, P. M., Paull, K. D., Friend, S. H., & Weinstein, J. N. (1998) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci970085w · Cited by 106
Self-citationDiscovery and Development of Antineoplastic Agents from Natural Sources
Cragg, G. M. L., & Newman, D. J. (1999) · Cancer Investigation · doi:10.1080/07357909909011730 · Cited by 148
Discovery of anticancer agents of diverse natural origin
Kinghorn, A. D., de Blanco, E. J. C., Chai, H., Orjala, J., Farnsworth, N. R., Soejarto, D. D., Oberlies, N. H., Wani, M. C., Kroll, D. J., Pearce, C. J., et al. (2009) · Pure and Applied Chemistry · doi:10.1351/pac-con-08-10-16 · Cited by 120
Eldehna, W. M., Abou‐Seri, S. M., Kerdawy, A. M. E., Ayyad, R. R. A., Hamdy, A. M., Ghabbour, H. A., Ali, M. M., & Ella, D. A. A. E. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.029 · Cited by 104
Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones
Havrylyuk, D., Zimenkovsky, B. S., Vasylenko, O., Day, C. W., Smee, D. F., Grellier, P., & Lesyk, R. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.05.044 · Cited by 103
Synthesis and antitumor evaluation of trimethoxyanilides based on 4(3H)-quinazolinone scaffolds
Mohamed, M. A., Ayyad, R. R. A., Shawer, T. Z., Abdel‐Aziz, A. A. ‐., & El‐Azab, A. S. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.02.002 · Cited by 103
Kulabaş, N., Tatar, E., Özakpınar, Ö. B., Özsavcı, D., Pannecouque, C. C., Clercq, E. D., & Küçükgüzel, İ. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.017 · Cited by 110
Antony, S., Jayaraman, M., Laco, G. S., Kohlhagen, G., Kohn, K. W., Cushman, M., & Pommier, Y. G. (2003) · PubMed · Cited by 102
Jada, S. R., Matthews, C., Saad, M. S., Hamzah, A. S., Lajis, N. H., Stevens, M. F. G., & Stanslas, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.368 · Cited by 102
Lesyk, R., Zimenkovsky, B. S., Atamanyuk, D. V., Jensen, F., Kieć‐Kononowicz, K., & Gzella, A. K. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.03.053 · Cited by 102
Flavopiridol binds to duplex DNA.
Bible, K. C., Bible, R. H., Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y., Hajdu, E., & Kaufmann, S. H. (2000) · PubMed · Cited by 113
Synthesis and in vitro anticancer activity of 2,4-azolidinedione-acetic acids derivatives
Kaminskyy, D. V., Zimenkovsky, B. S., & Lesyk, R. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.02.023 · Cited by 100
Review of Cytotoxic Cephalostatins and Ritterazines: Isolation and Synthesis
Moser, B. R. (2008) · Journal of Natural Products · doi:10.1021/np070536z · Cited by 99
Antileukemic activity of aminoparthenolide analogs
Nasim, S., & Crooks, P. A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.050 · Cited by 99
Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines
Weinstein, J. N. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0640 · Cited by 97
Kim, J.-H., Bogner, P. N., Baek, S.-H., Ramnath, N., Liang, P., Kim, H.-R., Andrews, C., & Park, Y. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4457 · Cited by 99
Fennell, B. J., Carolan, S., Pettit, G. R., & Bell, A. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg151 · Cited by 99
Ali, A. R., El‐Bendary, E. R., Ghaly, M. A., & Shehata, I. A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.12.010 · Cited by 99
Eldehna, W. M., Abo-Ashour, M. F., Ibrahim, H. S., Al-Ansary, G. H., Ghabbour, H. A., Elaasser, M. M., Ahmed, H. Y., & Safwat, N. A. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1421181 · Cited by 99
Maher, M., Kassab, A. E., Zaher, A. F., & Mahmoud, Z. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1564046 · Cited by 98
Singla, P., Luxami, V., & Paul, K. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.012 · Cited by 98
Diana, P., Martorana, A., Barraja, P., Montalbano, A., Dattolo, G., Cirrincione, G., Dall’Acqua, F., Salvador, A., Vedaldi, D., Basso, G., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm070834t · Cited by 115
Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalina spp. sponges
Gamble, W. R., Durso, N. A., Fuller, R. W., Westergaard, C. K., Johnson, T. R., Sackett, D. L., Hamel, E., Cardellina, J. H., & Boyd, M. R. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00089-9 · Cited by 98
Self-citationNovel 2-methoxyestradiol analogues with antitumor activity.
Tinley, T. L., Leal, R. M., Randall‐Hlubek, D. A., Cessac, J. W., Wilkens, L. R., Rao, P. N., & Mooberry, S. L. (2003) · PubMed · Cited by 104
Oku, N., Takada, K., Fuller, R. W., Wilson, J. A., Peach, M. L., Pannell, L. K., McMahon, J. B., & Gustafson, K. R. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1016766 · Cited by 95
Synthesis of novel 1,2,5-trisubstituted benzimidazoles as potential antitumor agents
Abonía, R., Cortés, E., Braulio Insuasty, O., Jairo Quiroga, P., Nogueras, M., & Cobo, J. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.06.006 · Cited by 95
Cytotoxic analogues of 2,6-bis(arylidene)cyclohexanones
Dimmock, J. R., Padmanilayam, M. P., Zello, G. A., Nienaber, K. H., Allen, T. M., Santos, C. L., Clercq, E. D., Balzarini, J. M., Manavathu, E. K., & Stables, J. P. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(02)01444-7 · Cited by 95
Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity
Subtel’na, I., Atamanyuk, D. V., Szymańska, E., Kieć‐Kononowicz, K., Zimenkovsky, B. S., Vasylenko, O., Gzella, A. K., & Lesyk, R. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.073 · Cited by 94
Synthesis of new pyrazole derivatives and their anticancer evaluation
Nițulescu, G. M., Draghici, C. C., & Missir, A. V. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.07.064 · Cited by 94
Synthesis and antitumour activity of 4-hydroxy-2-pyridone derivatives
Cocco, M. T., Congiu, C., & Onnis, V. (2000) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(00)00149-5 · Cited by 94
Blower, P. E., Yang, C., Fligner, M. A., Verducci, J. S., Yu, L., Richman, S., & Weinstein, J. N. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500116 · Cited by 99
Synthesis of 1,2,3-Triazole Derivatives and Evaluation of their Anticancer Activity
Pokhodylo, N. T., Shyyka, O., & Matiychuk, V. (2013) · Scientia Pharmaceutica · doi:10.3797/scipharm.1302-04 · Cited by 92
Onnis, V., Cocco, M. T., Fadda, R., & Congiu, C. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.07.066 · Cited by 92
Application of High-Throughput, Molecular-Targeted Screening to Anticancer Drug Discovery
Shoemaker, R., Scudiero, D., Melillo, G., Currens, M., Monks, A., Rabow, A., Covell, D., & Sausville, E. (2002) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026023394317 · Cited by 91
NCI-60 Cell Line Screening: A Radical Departure in its Time
Chabner, B. A. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv388 · Cited by 92
Mutanyatta, J., Matapa, B. G., Shushu, D. D., & Abegaz, B. M. (2003) · Phytochemistry · doi:10.1016/s0031-9422(02)00622-2 · Cited by 90
Abad, A., López‐Pérez, J. L., del Olmo, E., García‐Fernández, L., Francesch, A., Trigili, C., Barasoaín, I., Andreu, J. M., Díaz, J. F., & Feliciano, A. S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2017573 · Cited by 89
Al‐Saadi, M. S., Faidallah, H. M., & Rostom, S. A. F. (2008) · Archiv der Pharmazie · doi:10.1002/ardp.200800026 · Cited by 89
A Facile Synthesis and Anticancer Activity Evaluation of Spiro[Thiazolidinone-Isatin] Conjugates
Kaminskyy, D. V., Khyluk, D., Vasylenko, O., Zaprutko, L., & Lesyk, R. (2011) · Scientia Pharmaceutica · doi:10.3797/scipharm.1109-14 · Cited by 89
Bekircan, O., Kuexuek, M., Kahveci, B., & Kolaylı, S. (2005) · Archiv der Pharmazie · doi:10.1002/ardp.200400964 · Cited by 88
Núñez, L. E., Nybo, S. E., González‐Sabín, J., Pérez, M. D., Menéndez, N., Braña, A. F., Shaaban, K. A., He, M., Morís, F., Salas, J. A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300234t · Cited by 94
Kamal, Ä., Khan, M. N. A., Reddy, K. S., & Rohini, K. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.027 · Cited by 88
El‐Subbagh, H. I., & Al-Obaid, A.-R. M. A. (1996) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(97)86181-8 · Cited by 88
The molecular pharmacology of symplostatin 1: A new antimitotic dolastatin 10 analog
Mooberry, S. L., Leal, R. M., Tinley, T. L., Luesch, H., Moore, R. E., & Corbett, T. H. (2003) · International Journal of Cancer · doi:10.1002/ijc.10982 · Cited by 87
Lesyk, R., Zimenkovsky, B. S., Kaminskyy, D. V., Kryshchyshyn‐Dylevych, A., Havryluk, D. Y., Atamanyuk, D. V., Subtel’na, I., & Khyluk, D. (2011) · Biopolymers and Cell · doi:10.7124/bc.000089 · Cited by 87
Gmeiner, W. H., Reinhold, W. C., & Pommier, Y. G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0674 · Cited by 89
Synthesis and anticancer activity of oxindole derived imidazo[1,5-a]pyrazines
Kamal, Ä., Ramakrishna, G., Raju, P. V. K., Rao, A., Viswanath, A., Nayak, V., & Sistla, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.027 · Cited by 86
Cocco, M. T., Congiu, C., Lilliu, V., & Onnis, V. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2005.07.005 · Cited by 86
Mining and Visualizing Large Anticancer Drug Discovery Databases
Shi, L. M., Fan, Y., Lee, J. K., Waltham, M. C., Andrews, D. T., Scherf, U., Paull, K. D., & Weinstein, J. N. (1999) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci990087b · Cited by 86
Self-citationP450 enzyme expression patterns in the NCI human tumor cell line panel.
Yu, L. J., Matias, J., Scudiero, D. A., Hite, K. M., Monks, A. P., Sausville, E. A., & Waxman, D. J. (2001) · PubMed · Cited by 86
Cinelli, M. A., Morrell, A. E., Dexheimer, T. S., Scher, E. S., Pommier, Y. G., & Cushman, M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800259e · Cited by 85
El‐Gohary, N. S., & Shaaban, M. I. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.02.010 · Cited by 85
Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols
Bradshaw, T. D., Matthews, C. S., Cookson, J., Chew, E.-H., Shah, M., Bailey, K., Monks, A., Harris, E., Westwell, A. D., Wells, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4141 · Cited by 83
A protein expression database for the molecular pharmacology of cancer
Myers, T. G., Anderson, N. L., Waltham, M., Li, G., Buolamwini, J. K., Scudiero, D. A., Paull, K. D., Sausville, E. A., & Weinstein, J. N. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150180351 · Cited by 86
Self-citationEldehna, W. M., Hassan, G. S., Al‐Rashood, S. T., Al-Warhi, T. I., Altyar, A. E., Alkahtani, H. M., Almehizia, A. A., & Abdel‐Aziz, H. A. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1547286 · Cited by 84
Nemr, M. T. M., & AboulMagd, A. M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104134 · Cited by 84
Metadata
- Authors
- Boyd, M. R., & Paull, K. D.
- Affiliations
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Corresponding author
- Boyd, Michael R.
- ORCID
- Boyd, Michael R.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 1995-02
- Volume
- 34
- Issue
- 2
- Pages
- 91-109
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2118909720
- Cited by
- 1,572
- References
- 40
- Citations by year
- 2026: 28 · 2025: 57 · 2024: 79 · 2023: 58 · 2022: 68 · 2021: 81 · 2020: 74 · 2019: 51 · 2018: 58 · 2017: 39 · 2016: 56 · 2015: 61 · 2014: 78 · 2013: 84 · 2012: 79
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Development Research (publishedVersion, public-domain)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anticancer drug discovery, human cancer cell lines, anticancer activity, lead compound identification, mechanism of action
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.